ALKBH5 and head and neck squamous cell carcinoma: Recently, a novel mechanism by which ALKBH5 drives an immune-inhibitory TIME was revealed by Jin et al. ALKBH5 overexpression in head and neck squamous cell carcinoma hindered RIG-1-mediated IFNα secretion, decreasing tumour-killing immune cell infiltration in the TIME and exerting a tumour-promoting effect [133].